UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 109

Sortiert nach

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

BMC cancer, 2018-12, Vol.18 (1), p.1298-10, Article 1298

2018

Volltextzugriff (PDF)

Effects of Implementing a Brief Family Nursing Intervention With Hospitalized Oncology Patients and Their Families in Germany: A Quasi-Experimental Study

Journal of family nursing, 2020-11, Vol.26 (4), p.346-357

2020

Volltextzugriff (PDF)

Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients

Cancer chemotherapy and pharmacology, 2008-09, Vol.62 (4), p.685-688

2008

Volltextzugriff (PDF)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3401-3411

2019

Volltextzugriff (PDF)

Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer

Journal of clinical oncology, 1999-02, Vol.17 (2), p.529-533

1999

Volltextzugriff (PDF)

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Journal of clinical oncology, 2004-04, Vol.22 (7), p.1188-1194

2004

Volltextzugriff (PDF)

Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma

Cancer biotherapy & radiopharmaceuticals, 2004-06, Vol.19 (3), p.331-342

2004

Volltextzugriff (PDF)

Abstract 2861: Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas

Cancer research (Chicago, Ill.), 2014-10, Vol.74 (19_Supplement), p.2861-2861

2014

Volltextzugriff (PDF)

Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma

Cancer biotherapy & radiopharmaceuticals, 2008-02, Vol.23 (1), p.129

2008

Volltextzugriff (PDF)

Does addition of 13-cis-retinoic acid to interferon-[alpha]2a improve survival in patients with metastatic RCC?

Nature reviews. Urology, 2006-02, Vol.3 (2), p.82

Atzpodien, Jens

2006

Volltextzugriff (PDF)

A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging

JNCI cancer spectrum, 2018-07, Vol.2 (3), p.pky032-pky032

2018

Volltextzugriff (PDF)

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

International journal of cancer, 1999-01, Vol.80 (2), p.219-230

1999

Volltextzugriff (PDF)

Abstract 5070: Validation of a fresh-tissue based prognostic gene signature in formalin-fixed, paraffin-embedded melanomas

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5070-5070

2011

Volltextzugriff (PDF)

Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients

Cancer chemotherapy and pharmacology, 2009-10, Vol.64 (5), p.901-905

2009

Volltextzugriff (PDF)

Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan

American journal of clinical oncology, 2011-02, Vol.34 (1), p.2-5

2011

Volltextzugriff (PDF)

Abstract 4652: Identification and validation of a novel nine-gene signature predicting clinical outcome in malignant melanoma

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.4652-4652

2010

Volltextzugriff (PDF)

Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients

Cancer biotherapy & radiopharmaceuticals, 2006-06, Vol.21 (3), p.206

2006

Volltextzugriff (PDF)

Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinoma

Cancer, 2002-09, Vol.95 (5), p.1045-1050

2002

Volltextzugriff (PDF)

Does addition of 13- cis -retinoic acid to interferon-α2a improve survival in patients with metastatic RCC?

Nature clinical practice urology, 2006-02, Vol.3 (2), p.82-83

Atzpodien, Jens

2006

Volltextzugriff (PDF)

Does addition of 13-cis-retinoic acid to interferon-alpha2a improve survival in patients with metastatic RCC?

Nature clinical practice urology, 2006-02, Vol.3 (2), p.82-83

Atzpodien, Jens

2006

Volltextzugriff (PDF)

Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients

The Journal of urology, 1996, Vol.155 (1), p.19-25

1996

Volltextzugriff (PDF)

GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients

Cancer biotherapy & radiopharmaceuticals, 2007-08, Vol.22 (4), p.551

2007

Volltextzugriff (PDF)

Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients

Cancer biotherapy & radiopharmaceuticals, 2008-08, Vol.23 (4), p.451

2008

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(84)

Publikationsform

Artikel
(108)
Reviews
(1)

Sprache

Englisch
(109)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Humans
(79)
Life Sciences & Biomedicine
(74)
Science & Technology
(74)
Oncology
(52)
Biological And Medical Sciences
(50)
Medical Sciences
(46)
Middle Aged
(45)
Male
(43)
Female
(41)
Adult
(36)
Aged
(36)
Immunotherapy
(27)
Pharmacology. Drug Treatments
(26)
Antineoplastic Agents
(24)
Pharmacology & Pharmacy
(20)
Medicine, Research & Experimental
(19)
Research & Experimental Medicine
(19)
Radiology, Nuclear Medicine & Medical Imaging
(17)
Prognosis
(15)
Interleukin-2 - Therapeutic Use
(14)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Effects of Implementing a Brief Family Nursing Intervention With Hospitalized Oncology Patients and Their Families in Germany: A Quasi-Experimental Study

Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer

Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status: Analysis of untreated RAS-wildtype mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109)

Tumor dynamics with fluorouracil/folinic acid, irinotecan, and oxaliplatin (FOLFOXIRI) plus panitumumab (pmab) or FOLFOXIRI alone as initial treatment of RAS wildtype metastatic colorectal cancer (mCRC): Central radiologic review of VOLFI—A randomized, open label, phase-2 study (AIO KRK0109)

Interleukin-2- and Interferon Alfa-2a-Based Immunochemotherapy in Advanced Renal Cell Carcinoma: A Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN)

Predictive impact of retinoid X receptor-alpha-expression in renal-cell carcinoma

Abstract 2861: Independent validation of a prognostic gene-signature based risk score in formalin-fixed paraffin-embedded melanomas

Peripheral blood neutrophils as independent immunologic predictor of response and long-term survival upon immunotherapy in metastatic renal-cell carcinoma

Does addition of 13-cis-retinoic acid to interferon-[alpha]2a improve survival in patients with metastatic RCC?

A Prognostic Gene Signature Expressed in Primary Cutaneous Melanoma: Synergism With Conventional Staging

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1

Abstract 5070: Validation of a fresh-tissue based prognostic gene signature in formalin-fixed, paraffin-embedded melanomas

Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients

Age has no significant impact on overall survival and on treatment tolerability in relapsed stage IV cutaneous malignant melanoma patients receiving Cisplatin, Gemcitabine, and Treosulfan

Abstract 4652: Identification and validation of a novel nine-gene signature predicting clinical outcome in malignant melanoma

Long-term maintenance therapy in interferon-alpha2a/interleukin-2-pretreated advanced renal-cell carcinoma patients

Thirteen‐year, long‐term efficacy of interferon 2α and interleukin 2‐based home therapy in patients with advanced renal cell carcinoma

Does addition of 13- cis -retinoic acid to interferon-α2a improve survival in patients with metastatic RCC?

Does addition of 13-cis-retinoic acid to interferon-alpha2a improve survival in patients with metastatic RCC?

Interleukin-2 Based Home Therapy of Metastatic Renal Cell Carcinoma: Risks and Benefits in 215 Consecutive Single Institution Patients

GM-CSF plus antigenic peptide vaccination in locally advanced melanoma patients

Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients

Suchergebnisse filtern